Bioactivity Comments

In humans lebrikizumab has systemic effects on markers of Th2 inflammation. Lebrikizumab treatment reduces serum immunoglobulin E (IgE) and interleukin-13 and -17 levels by approximately 25% [5]. The development of lebrikizumab is covered by patent US7674459, in which it appears to be the monoclonal designated as 228B/C-1 [3]. No binding constant is provided in this patent, although a graph representing binding of 228B/C-1 to IL-13 in an ELISA suggests a half max value of approximately 0.1nM.

Selectivity at ligand targets
Key to terms and symbols		Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference IL-13 Hs Antibody Binding 9.9 pKd - 8 ⤷ pKd 9.9 (Kd 1.31x10-10 M) [8] Description: Binding affinity determined by SPR